Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan

POXEL SA, Lyon, February 3rd, 2026 a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, announces the implementation of an equity line with IRIS, known as “SmartATM^® “ for a maximum amount of €5 million over five years (terms set out in the Appendix without this amount being guaranteed).

Download Poxel press release